WILMINGTON, Delaware, June 13 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

TRUQAP(R) (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19%

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:

What's your Affiliation

Government Newspaper / Media Business Public Policy Individual / Student Educators

Email:

Phone:

Organization, if any:

State/Country you are in:

Additional questions or comments:

Submit Form Click here for more information about our products